Ortho-Clinical Diagnostics, Inc.
$10.7M 232 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
TG Therapeutics, Inc.
TG Therapeutics, Inc. reported $10,712,173.41 across General Payments, Research, and Ownership to 12,185 physicians and teaching hospitals across 13,349 transactions.
- $10.7M
- All-tracks total
- 13,349
- Transactions
- 12,185
- Recipients
- +$2.1M
- General Payments vs PY2023
TG Therapeutics, Inc. reported $10,712,173.41 across all CMS Open Payments tracks (General + Research + Ownership) to 12,185 physicians and teaching hospitals in Program Year 2024 - ranking #161 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $4,749,503.99, averaging $879.13 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer tg-therapeutics-inc TG Therapeutics, Inc.
$10.7M · #161/1,925 · 0.1% industry · PY2024
- TOT $10.7M
- RANK #161
- SHARE 0.1%
- TXN 13,349
- RCP 12,185
- CAT 8
- GEN $4.7M
- ΔGEN +$2.1M
- TOP1 9.8%
- PY 2024
Volume peers
Nearest volume peer: Ortho-Clinical Diagnostics, Inc. ($10.7M)
TG Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
TG Therapeutics, Inc.'s CMS-reported General Payments increased by $2.1M (+81.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TG THERAPEUTICS, INC.PY2023: TG THERAPEUTICS, INC.PY2024: TG Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,616,354.93
- PY2024
- $4,749,503.99
What the Data Shows for TG Therapeutics, Inc.
TG Therapeutics, Inc. ranks #161 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.1% slice of all industry payments reported nationwide for the year. The underlying total is $10,712,173.41 across 13,349 transactions to 12,185 physicians and teaching hospitals - $802.47 per transaction and $879.13 per recipient on average.
"Compensation for Services Other Than Consulting" leads the 8-category general-payment breakdown below at $3.5M (72.9% of General Payments, 1,170 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
TG Therapeutics, Inc. made 8 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $3.5M, 72.9% of General Payments.
TG Therapeutics, Inc. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (72.9%), Travel and Lodging (8.5%), and Consulting Fee (8.4%). The remaining 5 categories make up 10.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: TG Therapeutics, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How TG Therapeutics, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $3.5M | 1,170 | 72.9% |
| Travel and Lodging | $403.0K | 945 | 8.5% |
| Consulting Fee | $397.7K | 292 | 8.4% |
| Food and Beverage | $355.5K | 9,755 | 7.5% |
| Space Rental or Facility Fees | $68.2K | 18 | 1.4% |
| Grant | $33.6K | 1 | 0.7% |
| Charitable Contribution | $30.0K | 2 | 0.6% |
| Education | $69.92 | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $844,141.01 (17.8%) of $4,749,503.99 in this company's General Payments records across 3,126 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for TG Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Sagar Lonial
$465,632.50 across 5 reported transactions
- 2
Mary Ann Picone
$132,898.65 across 103 reported transactions
- 3
Barry Singer
$89,131.84 across 60 reported transactions
- 4
Mark Tullman
$80,547.65 across 62 reported transactions
- 5
David Clark
$75,930.37 across 58 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as TG Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about TG Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with TG Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sanofi-Aventis U.s. LLC
$10.7M 42,061 recipients
Compare payment profiles
Lexicon Pharmaceuticals, Inc.
$10.7M 20,498 recipients
Compare payment profiles
Alafair Biosciences, Inc.
$10.8M 704 recipients
Compare payment profiles
Astellas Pharma US Inc
$10.6M 147,377 recipients
Compare payment profiles
Glaukos Corporation
$10.8M 11,456 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.